| |
Home : N : Naratriptan HCl : Frovatriptan Succinate and Naratriptan HCl
Effects and Recommendation :
Resulting In: coronary artery vasospasm Concomitant use of Frovatriptan Succinate and Naratriptan HCl may increase the risk of vasospasm.
Combination of 5-HT1 receptor agonists within a 24-hour period is contraindicated.
Severity of the interaction : 6/6
|
Information on this interaction is found in the following publications :
----------
Product Information. Frova (frovatriptan succinate). Elan Pharmaceuticals, 2001.
Publication : Frova (frovatriptan succinate) by Product Information
> Product Information - -
|
|
|
|
|
